FDA Brief

Warning letters Biologics

FDA warning letter to

Berkeley Biologics, LLC, previously operating as Elutia, Inc. – Orthobiologics Business Unit, formerly Aziyo Biologics, Inc.

High riskIssued Jun 28, 2024Posted Aug 27, 2024Center for Biologics Evaluation and Research (CBER)

FDA says Berkeley Biologics' viable bone matrix products are unapproved drugs, with donor screening failures tied to tuberculosis infections.

What happened

FDA inspected the Richmond, California plant from September 05, 2023 to September 25, 2023 and reviewed the company's records. Investigators found the company accepted donors with documented sepsis and used their bone tissue to make products implanted into patients, some linked to an outbreak of Mycobacterium tuberculosis infections. FDA also found manufacturing and testing shortfalls, and said the products are unapproved new drugs because no biologics license or investigational application is in effect for them.

What FDA found

  1. The company's donor screening procedure did not rule out donors with sepsis, a disease that can be passed through tissue, so tissue from these donors was made into products and implanted.

    21 CFR 1271.75(d)(1)
  2. The company had no adequate written production and process controls, and its process validation accepted batches that failed its own criteria and did not test for identity, strength, quality and purity.

    21 CFR 211.100(a)
  3. Aseptic processing controls were inadequate: microbial limits inside the biosafety cabinet were set too high, critical surfaces were not sampled each batch, and operators' forearms and sleeves were not monitored.

    21 CFR 211.42(c)(10)(iv)
  4. Laboratory controls were inadequate: finished product testing was limited to sterility, and sterility samples were frozen before testing, which could hide contamination.

    21 CFR 211.160(b)
  5. The products are unapproved new drugs sold across state lines without an approved biologics license or an investigational new drug application in effect.

    FD&C Act sections 301(d) and 505(a); PHS Act section 351(a)(1)
  6. The products fail the minimal manipulation and no-added-article criteria, so they cannot be regulated only as tissue products and need premarket review.

    21 CFR 1271.10(a)(1) and 21 CFR 1271.10(a)(3)

What FDA wants

FDA wants a written reply within 15 working days describing specific corrective steps, with documentation, and a list of all donors with sepsis risk factors or evidence who were ruled eligible, plus the products made from them. The company must also revise its sepsis screening procedure and address products already on the market and the manufacturing violations.

Who should pay attention

  • hospitals and surgeons implanting bone graft or tissue-based products
  • distributors and sales agents handling human tissue products
  • tissue banks and contract manufacturers doing aseptic processing of human tissue

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Central Coast Multispecialty Medical Group, Inc.

    FDA warns Central Coast Multispecialty Medical Group over incomplete donor screening and eligibility for reproductive tissue.

    High risk
  2. Conceive Fertility Center

    FDA says Conceive Fertility Center in Dallas used incomplete donor screening and testing for reproductive cells.

    High risk
  3. Louisville Reproductive Center

    Louisville Reproductive Center failed to properly test and screen semen donors for infectious diseases, FDA found.

    High risk
  4. Green Valley Fertility Partners

    FDA cited Green Valley Fertility Partners for donor eligibility failures involving oocyte HCT/Ps, including missing communicable disease testing and screening.

    High risk